Literature DB >> 30191019

Apoptosis in liver carcinogenesis and chemotherapy.

Joaquim Moreno-Càceres1,1, Isabel Fabregat1,2,1,2.   

Abstract

Hepatocellular carcinoma (HCC) is a major health problem. In human hepatocarcinogenesis, the balance between cell death and proliferation is deregulated, tipping the scales for a situation where antiapoptotic signals are overpowering the death-triggering stimuli. HCC cells harbor a wide variety of mutations that alter the regulation of apoptosis and hence the response to chemotherapeutical drugs, making them resistant to the proapoptotic signals. Considering all these modifications found in HCC cells, therapeutic approaches need to be carefully studied in order to specifically target the antiapoptotic signals. This review deals with the recent relevant contributions reporting molecular alterations for HCC that lead to a deregulation of apoptosis, as well as the challenge of death-inducing chemotherapeutics in current HCC treatment.

Entities:  

Keywords:  HCC; TGF-β; apoptosis; death receptors; liver; sorafenib; survival signals; targeted therapy

Year:  2015        PMID: 30191019      PMCID: PMC6095415          DOI: 10.2217/hep.15.27

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN: 2045-0923


  159 in total

Review 1.  Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

Authors:  Edgar Pérez-Herrero; Alberto Fernández-Medarde
Journal:  Eur J Pharm Biopharm       Date:  2015-03-23       Impact factor: 5.571

2.  c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.

Authors:  Hanning You; Wei Ding; Hien Dang; Yixing Jiang; C Bart Rountree
Journal:  Hepatology       Date:  2011-07-19       Impact factor: 17.425

3.  Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas.

Authors:  W Beerheide; Y J Tan; E Teng; A E Ting; A Jedpiyawongse; P Srivatanakul
Journal:  Biochem Biophys Res Commun       Date:  2000-06-24       Impact factor: 3.575

4.  siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells.

Authors:  Wensong Liu; Feng Zhu; Yong Jiang; Donglin Sun; Bo Yang; Haijiao Yan
Journal:  Oncol Rep       Date:  2012-12-18       Impact factor: 3.906

5.  A novel interaction of nucleophosmin with BCL2-associated X protein regulating death evasion and drug sensitivity in human hepatoma cells.

Authors:  Shao-Jung Lo; Li-Ching Fan; Yow-Fu Tsai; Kuo-Yang Lin; Hsiao-Ling Huang; Tong-Hong Wang; Hsuan Liu; Tse-Chin Chen; Shiu-Fen Huang; Chee-Jen Chang; Yu-Jr Lin; Benjamin Yat-Ming Yung; Sen-Yung Hsieh
Journal:  Hepatology       Date:  2013-04-01       Impact factor: 17.425

6.  Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma.

Authors:  Hiroshi Okano; Katsuya Shiraki; Hidekazu Inoue; Tomoyuki Kawakita; Takenari Yamanaka; Masatoshi Deguchi; Kazushi Sugimoto; Takahisa Sakai; Shigeru Ohmori; Katsuhiko Fujikawa; Kazumoto Murata; Takeshi Nakano
Journal:  Lab Invest       Date:  2003-07       Impact factor: 5.662

7.  Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge.

Authors:  F van Zijl; M Mair; A Csiszar; D Schneller; G Zulehner; H Huber; R Eferl; H Beug; H Dolznig; W Mikulits
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

8.  A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.

Authors:  Joan Fernando; Andrea Malfettone; Edgar B Cepeda; Roser Vilarrasa-Blasi; Esther Bertran; Giulia Raimondi; Àngels Fabra; Alberto Alvarez-Barrientos; Pedro Fernández-Salguero; Conrado M Fernández-Rodríguez; Gianluigi Giannelli; Patricia Sancho; Isabel Fabregat
Journal:  Int J Cancer       Date:  2014-08-04       Impact factor: 7.396

9.  The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes.

Authors:  Francisco Valdés; Alberto M Alvarez; Annamaria Locascio; Sonia Vega; Blanca Herrera; Margarita Fernández; Manuel Benito; M Angela Nieto; Isabel Fabregat
Journal:  Mol Cancer Res       Date:  2002-11       Impact factor: 5.852

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  7 in total

Review 1.  Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies.

Authors:  Jens U Marquardt; Frank Edlich
Journal:  Front Oncol       Date:  2019-12-13       Impact factor: 6.244

2.  Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells.

Authors:  Xiao-Jing Yan; Peng Xie; Xu-Fang Dai; Ling-Xi Chen; Liang-Bo Sun; Tao Li; Wen-Hui He; Zhi-Zhen Xu; Gang Huang; Feng-Tian He; Ji-Qin Lian
Journal:  Cancer Drug Resist       Date:  2020-09-04

3.  Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β.

Authors:  Leah M Alabanza; Ying Xiong; Bang Vu; Brian Webster; Darong Wu; Peirong Hu; Zhongyu Zhu; Boro Dropulic; Pradyot Dash; Dina Schneider
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

4.  Inhibitory effects of LOXL2 knockdown on cellular functions of liver cancer stem cells.

Authors:  Na Li; Huan Gu; Liu Liu; Xiao-Li Zhang; Qiu-Luo Cheng; Ying Zhu
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

5.  The Phenoxyphenol Compound diTFPP Mediates Exogenous C2-Ceramide Metabolism, Inducing Cell Apoptosis Accompanied by ROS Formation and Autophagy in Hepatocellular Carcinoma Cells.

Authors:  Wen-Tsan Chang; Yung-Ding Bow; Yen-Chun Chen; Chia-Yang Li; Jeff Yi-Fu Chen; Yi-Ching Chu; Yen-Ni Teng; Ruei-Nian Li; Chien-Chih Chiu
Journal:  Antioxidants (Basel)       Date:  2021-03-05

Review 6.  The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target.

Authors:  Yun Yang; Wen-Long Ye; Ruo-Nan Zhang; Xiao-Shun He; Jing-Ru Wang; Yu-Xuan Liu; Yi Wang; Xue-Mei Yang; Yu-Juan Zhang; Wen-Juan Gan
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-22       Impact factor: 2.629

Review 7.  Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Authors:  Sara M Atwa; Margarete Odenthal; Hend M El Tayebi
Journal:  Cancers (Basel)       Date:  2021-08-27       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.